Analysts have to CTA and hedge their bets in order to keep their jobs when recommendations go awry. Low-balling revenue estimates and price objectives is just part of their process. The centuries-old need to have a working lupus-nephritis treatment available is an amazingly compelling story. The FDA is on the brink of allowing a fledgling company in the door that succeeded when a few of the FDA's big-old buddies failed. The DES story is equally a game-changer because it shot an existing, approved product, created by a huge company, right out of the water.
News 
Market Data 
Discover 
AI
